Compass Therapeutics, Inc. (NASDAQ:CMPX) Short Interest Update

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,210,000 shares, an increase of 5.2% from the December 31st total of 2,100,000 shares. Approximately 2.6% of the company’s stock are short sold. Based on an average daily trading volume, of 875,000 shares, the days-to-cover ratio is currently 2.5 days.

Compass Therapeutics Stock Up 1.3 %

CMPX opened at $3.12 on Wednesday. The company’s 50-day moving average price is $1.96 and its 200 day moving average price is $1.67. Compass Therapeutics has a fifty-two week low of $0.76 and a fifty-two week high of $3.63. The firm has a market cap of $429.28 million, a price-to-earnings ratio of -8.43 and a beta of 1.15.

Compass Therapeutics (NASDAQ:CMPX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.03. Research analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current year.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC grew its position in shares of Compass Therapeutics by 921.6% during the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock worth $573,000 after acquiring an additional 356,352 shares during the last quarter. Barclays PLC grew its position in Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after purchasing an additional 112,614 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after purchasing an additional 70,200 shares during the period. Catalina Capital Group LLC acquired a new stake in shares of Compass Therapeutics in the fourth quarter valued at approximately $71,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Compass Therapeutics during the third quarter valued at approximately $79,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CMPX shares. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $5.00 to $4.00 in a report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Compass Therapeutics in a research note on Wednesday, January 8th. D. Boral Capital reissued a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Finally, Leerink Partnrs downgraded Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 15th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $11.80.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.